論文業績

2024年

原著論文

1. Momosaka T, Saito J, Otsuki A, Yaguchi-Saito A, Fujimori M, Kuchiba A, Katanoda K, Takaku R, Shimazu T. Associations of individual characteristics and socioeconomic status with heated tobacco product harmfulness perceptions in Japan: A nationwide cross-sectional study (INFORM Study 2020) Journal of Epidemiology. 2024: in press [Pubmed].
2. Miyawaki R, Oka K, Otsuki A, Saito J, Yaguchi-Saito A, Kuchiba A, Fujimori M, Kreps GL, Shimazu T, for the INFORM Study Group. Trust in mass media as sources of cancer information: Findings from a nationally representative cross-sectional survey in Japan. Journal of Health Communication. 2024; 29(2):143-154 [Pubmed].

 

2023年

原著論文

1. Ando Y, Shimoi T, Sunami K, Okita N, Nakamura K, Shibata T, Fujiwara Y, Yamamoto N, Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE Trial, Cancer Sci, 2023 Dec 1. doi: 10.1111/cas.16034. [Pubmed]
2. Terada M, Shimazu T, Saito J, Odawara M, Otsuki A, Yaguchi-Saito A, Miyawaki R, Kuchiba A, Ishikawa H, Fujimori M, Kreps GL, for the INFORM Study Group. Age, gender and socioeconomic disparities in Human Papillomavirus (HPV) awareness and knowledge among Japanese adults after a 7-year suspension of proactive recommendation for the HPV vaccine: A nationally representative cross-sectional survey. Vaccine. 2023; 41(48):7147-7158 [Pubmed].
3. Ishikawa Y, Tokutsu K, Nakayamada S, Kuchiba A, Fushimi K, Matsuda S and  Tanaka Y. Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: A propensity score analysis of the real-world nationwide database. Annals of the Rheumatic Diseases. 2024; 83(1):103-111 [Pubmed].
4. Takahashi K, Yamamoto K, Kuchiba A, Shintani A, Koyama T. Hypothesis testing procedure for binary and multi-class F1-scores in the paired design. Statistics in Medicine. 2023;42(23):4177-4192 [Pubmed].
5. Nakano S, Yamaji T, Shiraishi K, Hidaka A, Shimazu T, Kuchiba A, Saito M, Kunishima F, Nakaza R, Kohno T, Sawada N, Inoue M, Tsugane S, and Iwasaki M, for the Japan Public Health Center-based Prospective Study Group. Smoking and risk of colorectal cancer according to KRAS and BRAF mutation statuses in a Japanese prospective study. Carcinogenesis．2023 ;44(6):476-484 [Pubmed].
6. Saito J, Odawara M, Fujimori M, Kuchiba A, Oyamada S, Saito E, Fukai K, Tatemichi M, Nakamura M, Uchitomi Y, Shimazu T. Interactive assistance via eHealth for small and medium-sized enterprise employers and healthcare manager teams on tobacco control (eSMART-TC): Protocol for a cluster randomized hybrid type II trial  (N-EQUITY2101/J-SUPPORT2102). Implementation Science Communications. 2023;4(1):61 [Pubmed].
7. Mieno MN, Yamasaki M, Kuchiba A, Yamaji T, Ide K, Tanaka N, Sawada N, Inoue M, Tsugane S, Sawabe M, Iwasaki M. Lack of significant associations between single nucleotide polymorphisms in LPAL2-LPA genetic region and all cancer incidence and mortality in Japanese population: the Japan Public Health Center-based Prospective Study. Cancer Epidemiology．2023 85:102395 [Pubmed].
8. Ishikawa H, Ogawa R, Otsuki A, Saito J, Yaguchi-Saito A, Kuchiba A, Fujimori M, Fukuda Y, Shimazu T, for the INFORM Study Group. Effect modification by geographic area on the association between health literacy and self-rated health: A nationwide cross-sectional study in Japan. BMC Public Health. 2023 ;23(1):952 [Pubmed].
9. Shida, D, Kuchiba A, Shibata T, Hamaguchi T, Yamasaki S, Ito M, Kobatake T, Tonooka T, Masaki T, Shiozawa M, Takii Y, Uetake H, Okamura S, Ojima H, Kazama S, Takeyama H, Kanato K, Shimada Y, Murakami Y, Kanemitsu Y. Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910. Cancer Science. 2023;114(8):3352-3363 [Pubmed].
10. Machida R, Sakamaki K, Kuchiba A. Clinical Trial Design and Analysis for Comparing Three Treatments with Intra-Individual Right- and Left-Hand Data. Clinical Trials. 2023 [Pubmed]

 

2022年

原著論文

1. Machida R, Sakamaki K, Kuchiba A. Clinical Trial Design and Analysis for Comparing Three Treatments with Intra-Individual Right- and Left-Hand Data. Clinical Trials. 2023 [Pubmed]
2. Araki Y, Yamamoto N, Tanzawa Y, Higashi T, Kuchiba A, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Endo M, Kobayashi E, Tsuchiya H, Kawai A. Family cancer history and smoking habit associated with sarcoma in a Japanese population study. Scientific Reports. 2022: 12(1):17129 [Pubmed] 
3. Yamada M, Shino R, Kondo H, Yamada S, Takamaru H, Sakamoto T, Bhandari P, Imaoka H, Kuchiba A, Shibata T, Saito Y, Hamamoto R. Robust automated prediction of the revised Vienna Classification in colonoscopy using deep learning: development and initial external validation. J Cancer Res Clin Oncol. 2022 Jul 28. [Pubmed]
4. Higashiyama RI, Horinouchi H, Kuchiba A, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients. J Cancer Res Clin Oncol. 2022. [Pubmed]
5. Nakamura K, Ozawa H, Shibata T, Ushirozawa N, Hata T, Okita N, Fuse N, Sato N, Ikeda K, Hanaoka H, Maruyama T, Wada M, Shimizu S, Kasai H, Yamamoto Y, Sakurai J, Todaka K, Tashiro S, Yamamoto H. Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation. Ther Innov Regul Sci. 2022 56(2):220-229. [PubMed]
6. Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022 18(19):2351-2360. [PubMed]
7. Takahashi K, Yamamoto K, Kuchiba A, Koyama T. Confidence interval for micro-averaged F₁ and macro-averaged F₁ scores. Appl Intell. 2022 52: 4961–4972. [PubMed]
8. Kikuchi K, Yamazaki N, Nozawa K, Fukuda H, Shibata T, Machida R, Hamaguchi T, Takashima A, Shoji H, Boku N, Takatsuka S, Takenouchi T, Nishina T, Yoshikawa S, Takahashi M, Hasegawa A, Kawazoe A, Masuishi T, Mizutani H, Kiyohara Y. Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part). Support Care Cancer. 2022 30(5):4497-4504. [PubMed]
9. Tsuji K, Matsuoka YJ, Kuchiba A, Suto A, Ochi E. Accuracy of exercise-based tests for estimating cardiorespiratory fitness and muscle strength in breast cancer survivors in Japan. Supportive Care in Cancer 2022 30(5):3857-3863. [PubMed]
10. Tsukamoto S, Kuchiba A, Moritani K, Shida D, Katayama H, Yorikane E,Kanemitsu Y. Laparoscopic surgery using 8 K ultra-high-definition technology: Outcomes of a phase II study. Asian J Endosc Surg. 2022 15(1):7-14. [PubMed]
11. Shimizu Y, Tsuji K, Ochi E, Okubo R, Kuchiba A, Shimazu T, Tatematsu N, Sakurai N, Iwata H, Matsuoka Y. Oncology care providers’ awareness and practice related to physical activity promotion for breast cancer survivors and barriers and facilitators to such promotion: A nationwide cross-sectional web-based survey. Supportive Care in Cancer 2022 30(4):3105-3118. [PubMed]
12. Oshima K, Kato K, Ito Y, Daiko H, Nozaki I, Nakagawa S, Shibuya Y, Kojima T, Toh Y, Okada M, Hironaka S, Akiyama Y, Komatsu Y, Maejima K, Nakagawa H, Onuki  R, Nagai M, Kato M, Kanato K, Kuchiba A, Nakamura K, Kitagawa Y. A prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1. Cancer Science 2022 113(3):1018-1027. [PubMed]

2021年

原著論文

1. Yuwaki K, Kuchiba A, Otsuki A, Odawara M, Okuhara T, Ishikawa H, Inoue M, Tsugane S, Shimazu T. Effectiveness of a cancer risk prediction tool on lifestyle habits: a randomized controlled trial. Cancer Epidemiology, Biomarkers & Prevention. 2021 30(6):1063-71. [PubMed]
2. Okuma HS, Yonemori K, Kojima Y, Tanioka M, Sudo K, Noguchi E, Hijioka S, Wakakuwa K, Kato K, Hirakawa A, Kuchiba A, Kubo T, Ichikawa H, Yoshida A, Yatabe Y, Nakamura K, Mano H, Yamamoto N, Yasuhiro F. Clinical utility of circulating tumor DNA profiling in advanced rare cancers. Frontiers in Oncology 2021 11:732525. [PubMed]
3. Shimomura A, Tamura K, Tanaka K, Mizutani T, Sasaki K, Sekino Y, Sawaki M, Shien T, Shibata T, Iwata H. A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study). Jpn J Clin Oncol. 2021 51(9):1471-1474. [PubMed]
4. Hara H, Uemura Y, Hayakawa K, Togano T, Asai Y, Matsunaga N, Terada M, Ohtsu H, Kitajima K, Shimizu Y, Sato L, Ishikane M, Kinoshita-Iwamoto N, Shibata T, Kondo M, Izumi K, Sugiura W, Ohmagari N. Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan, International Journal of Infectious Disesases. 2021 112時11分1-116. [PubMed]
5. Mizuno T, Yoshida T, Sunami K, Koyama T, Okita N, Kubo T, Sudo K, Shimoi T, Ueno H, Saito E, Katanoda K, Shibata T, Yonemori K, Okusaka T, Boku N, Ohe Y, Hiroshima Y, Ueno M, Kuboki Y, Doi T, Nakamura K, Kohno T, Yatabe Y, Yamamoto N. Study protocol for NCCH1908 (UPFRONT-trial): a prospective clinical trial to evaluate the feasibility and utility of comprehensive genomic profiling prior to the initial systemic treatment in advanced solid tumour patients. Jpn J Clin Oncol. 2021 51(12):1757-1760. [PubMed]
6. Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, Suzuki S, Toyoda A, Suzuki K, Endo M, Fujii N, Suzuki M, Saito S, Uemura Y, Shibata T, Kondo M, Izumi K, Terada-Hirashima J, Mikami A, Sugiura W, Ohmagari N. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY JAPAN. Clinical Infectious Diseases 2021 73(11):e3677-e3689. [PubMed]
7. Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, Nakai Y, Takahashi T, Shibata T, Hamaguchi T, Kikuchi K, Yamazaki N, Fukuda H, Nozawa K, Kiyohara Y. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). Supportive Care in Cancer. 2021 29(5):2327-2334. [PubMed]
8. Tagawa T, Yamada M, Minagawa T, Sekiguchi M, Konda K, Tanaka H, Takamaru H, Sekiguchi M, Sakamoto T, Matsuda T, Kuchiba A, Yoshida H, Saito Y. Endoscopic characteristics influencing postpolypectomy bleeding in consecutive 1147 pedunculated colonic polyps: a multicenter retrospective study. Gastrointest Endosc. 2021 94(4):803-811.e6. [PubMed]
9. Ishikawa M, Shibata T, Iwata T, Nishio S, Takada T, Suzuki S, Horie K, Kudaka W, Kagabu M, Tanikawa M, Kitagawa R, Takekuma M, Kobayashi H, Yaegashi N. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis. Gynecol Oncol. 2021 162(2):292-298. [PubMed]
10. Fujimoto K, Arita H, Satomi K, Yamasaki K, Matsushita Y, Nakamura T, Miyakita Y, Umehara T, Kobayashi K, Tamura K, Tanaka S, Higuchi F, Okita Y, Kanemura Y, Fukai J, Sakamoto D, Uda T, Machida R, Kuchiba A, Maehara T, Nagane M, Nishikawa R, Suzuki H, Shibuya M, Komori T, Narita Y, Ichimura K. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol. 2021 142(2):323-338. [PubMed]
11. Ochi E, Tsuji K, Narisawa T, ShimizuY, Kuchiba A, Suto A, Jimbo K, Takayama S, Ueno T, Sakurai N. Matsuoka YJ. Effect of home-based smartphone-supported high-intensity interval training on cardiorespiratory fitness in breast cancer survivors: a randomized controlled trial of the habit-B program. BMJ Supportive & Palliative Care. 2022 12(1):33-37. [PubMed]